Consumer Staples, Healthcare, Financials Jun 10, 2021 06:50 PM (GMT+8) · EqualOcean
Beida pharmaceutical announced that the company and Agnus jointly declared the evaluation of clinical trials of balstilimab injection (PD-1 antibody) alone or combined with zalifrelimab injection (CTLA-4 antibody) in the treatment of advanced cervical cancer, which has been approved by nmpa.
Related companies: